Fitch Upgrades Loma Linda University Medical Center's (CA) IDR to 'BB+'; Outlook Stable

Mon 14 Nov, 2022 - 1:26 PM ET

Fitch Ratings - Chicago - 14 Nov 2022: Fitch Ratings has upgraded Loma Linda University Medical Center's (LLUMC) Issuer Default Rating (IDR) to 'BB+' from 'BB'. Fitch has also upgraded to 'BB+' from 'BB' the ratings on revenue bonds issued by the California Statewide Communities Development Authority on behalf of LLUMC.

The Rating Outlook is Stable.

RATING ACTIONS

<table>
<thead>
<tr>
<th>ENTITY / DEBT</th>
<th>RATING</th>
<th>PRIOR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Loma Linda University Medical Center (CA)</td>
<td>LT IDR</td>
<td>BB Rating Outlook Stable</td>
</tr>
<tr>
<td></td>
<td>Upgrade</td>
<td>BB Rating Outlook Stable</td>
</tr>
</tbody>
</table>
The bonds are secured by a gross receivables pledge and a mortgage pledge of the obligated group (OG). There are also debt service reserve funds (DSRF) in place. The OG includes LLUMC, LLU Children's Hospital, the LLUMC - Murrieta hospital, and Loma Linda University Behavioral Medicine Center. The OG accounts for almost all of the consolidated system assets and revenues. Fitch's analysis is based on the consolidated system.

**ANALYTICAL CONCLUSION**

The upgrade to 'BB+' incorporates LLUMC's major new hospital, which is now open, and the system has been operating in their new environment for more than one year, removing a considerable risk factor. As the only academic medical center (AMC) and only children's hospital serving a large population base in the Inland Empire, LLUMC is well positioned from a competitive perspective.

Assuming a reasonable pace of operating performance, the system's capital-related metrics should show improvement over time, even under a stress case in Fitch's forward-looking scenario analysis, especially given that capital spending plans are somewhat limited and much of that capex is expected to be funded by external sources (e.g., State of California Prop 4 funding for children's hospitals).

**KEY RATING DRIVERS**

**Revenue Defensibility: 'bbb'**

**High Acuity Academic Provider in Challenging Market**

LLUMC's midrange revenue defensibility is characterized by its broad reach for tertiary and quaternary services as the only AMC and children's hospital covering a broad geography and population base in the Inland Empire service area, which includes the population centers of San Bernardino County and northern Riverside County. While competing hospitals are present and inpatient market share is dispersed among a number of providers, LLUMC is the exclusive or decidedly leading provider of many high-end services.
While Medi-Cal (Medicaid) and self-pay represent a very high 40% or more of LLUMC's gross revenue (including 41.5% in fiscal 2022), this is common for AMCs, particularly those that are designated trauma centers and those that include large children's hospitals (LLUMC's children's hospital represents nearly one-quarter of system total operating revenue).

Demographic indicators of the service area are generally considered to be stable. Both San Bernardino and Riverside counties are experiencing population growth slightly above the U.S. average. The unemployment rate in the Riverside-San Bernardino-Ontario MSA is just above the national average (per U.S. Bureau of Labor Statistics data).

LLUMC's revenue defensibility is bolstered by its strong relationship with Loma Linda University (LLU, IDR: A+). LLUMC's and LLU's campuses are adjacent. The university operates eight schools, seven of which are focused on healthcare education and research, including schools of medicine, nursing, and public health. While LLU and LLUMC are separate legal organizations and not obligated on each other's debt, they are tightly aligned and the medical system is integral to the university's teaching and research.

**Operating Risk: 'a'**

**Variable but Generally Good Operating Margins; Macro Pressures Present**

Historically, while variable, LLUMC's operating EBITDA margins are generally strong. Between fiscals 2017 and 2022, LLUMC's operating EBITDA margin averaged approximately 10% (ranging from a low of 6.5% in fiscal 2022 to a high of nearly 16% in fiscal 2018).

As the region's AMC and only children's hospital, demand for LLUMC is considerable and growing with the opening of the new Dennis and Carol Troesh medical campus in August 2021. Since opening the new hospital, many key volumes have increased noticeably, even though the first full fiscal year of the hospital will not be until fiscal 2023. Key areas of volume gain in fiscal 2022 over fiscal 2021 include inpatient admissions (up 3.4%, and up 8.7% including observation stays), unique patients (up nearly 17%), outpatient surgeries (up 8.0%), and outpatient visits (up 9.1%).

While these volume gains in fiscal 2022 were particularly notable given the surge in omicron variant COVID patients in late calendar 2021 and early calendar 2022, the ongoing nurse labor disruptions that have affected the entire sector have resulted in LLUMC facing fiscal challenges. Even with considerable demand, LLUMC's operating
Margins were compressed in fiscal 2022 with a -2.4% operating margin and 6.5% operating EBITDA margin. Like nearly the entire US hospital sector, LLUMC had to face material labor pressures, general inflation, and the omicron surge. LLUMC had to contend with these challenges while simultaneously bearing the burden of ramping up operations at the new hospital.

Looking forward, Fitch expects that despite ongoing macro pressures, LLUMC should generally generate good operating EBITDA margins, even if metrics do not quite match the strong results recorded prior to the pandemic. Operating margins likely will be variable as the state's Hospital Quality Assurance Fee Program is not distributed evenly (although on the whole this program provides considerable cash flow to LLUMC).

With the opening of the new hospital in late summer 2021, capital spending plans are limited at LLUMC. And much of the capex that is planned is expected to receive significant external support. For example, the planned LLUMC children's outpatient center is slated to receive as much as $135 million in voter approved state proposition 4 funding. LLUMC (and LLU) has a history of successful fundraising.

Financial Profile: 'bb'

Financial Profile Improving but Remains Modest

LLUMC’s financial profile is improving but still modest and consistent with a below investment grade rating. Nevertheless, key capital-related metrics should improve over time.

At audited FYE 2022 (June 30 year-end), LLUMC's unrestricted cash and investments exceeded $805 million (Medicare advances moved from unrestricted cash to restricted) and total debt was more than $2.2 billion. This translated to cash-to-debt of 43% at FYE 2022 (including DSRFs in the numerator).

LLUMC participates in the North American Division of Seventh-day Adventist multiemployer frozen defined benefit (DB) pension plan. The frozen DB plan was 100% funded as of the most recent measurement date (Jan. 1, 2021), so cash-to-adjusted debt is the same as cash-to-debt at 43% (Fitch only includes the portion of a DB pension plan that is below 80% funded when calculating adjusted debt).

LLUMC’s capital-related ratios should improve over time, even in a stress case of Fitch's forward-looking scenario analysis. In the stress case the net adjusted debt-to-adjusted
EBITDA ratio remains unfavorably positive, although approaches a more palatable 3x by year five. Cash-to-adjusted debt does not fall below 35% and reaches 50% by year four. Net adjusted debt-to-adjusted EBITDA consistently below 3x and cash-to-adjusted debt sustained above 50% would indicate a financial profile more consistent with an investment grade rating.

**Asymmetric Additional Risk Considerations**

No asymmetric additional risk considerations were applied in this rating determination.

Financial covenants in LLUMC's MTI include a minimum debt service coverage ratio of 1.1x and minimum cash on hand of 60 days. LLUMC met the financial covenants based on fiscal 2022 results (although debt service coverage would have been below 1.0x without QAF funding).

**RATING SENSITIVITIES**

Factors that could, individually or collectively, lead to negative rating action/downgrade:

-- Liquidity deterioration beyond Fitch's stress scenario leading to weaker cash-to-adjusted debt that is expected to remain below 40%;

-- Sustained thinner operating EBITDA margins that would be more consistent with a midrange operating risk profile assessment.

Factors that could, individually or collectively, lead to positive rating action/upgrade:

-- Improved cash-to-adjusted debt above 50%, particularly if the operating EBITDA margin is sustained in the 8% - 9% range.

**BEST/WORST CASE RATING SCENARIO**

International scale credit ratings of Sovereigns, Public Finance and Infrastructure issuers have a best-case rating upgrade scenario (defined as the 99th percentile of rating transitions, measured in a positive direction) of three notches over a three-year rating horizon; and a worst-case rating downgrade scenario (defined as the 99th percentile of rating transitions, measured in a negative direction) of three notches over three years. The complete span of best- and worst-case scenario credit ratings for all rating categories ranges from 'AAA' to 'D'. Best- and worst-case scenario credit ratings are based on historical performance. For more information about the methodology used to determine sector-
specific best- and worst-case scenario credit ratings, visit
https://www.fitchratings.com/site/re/10111579.

CREDIT PROFILE

LLUMC is part of Loma Linda University Health (LLUH), which also includes LLU, the Faculty Medical Group (LLUFMG), and several other related organizations. A board restructuring in April 2015 resulted in one unified board for the organization and the decision to coordinate fiscal year ends for all LLUH members.

LLUMC, located approximately 60 miles east of Los Angeles in Loma Linda, CA. The system operates 1,046 beds, including 364 Children's Hospital beds. LLUMC offers tertiary and quaternary series and has the only level I trauma center and level IV neonatal intensive care unit in the Inland Empire service area.

LLU is a private university affiliated with the Seventh-Day Adventist Church. It is the flagship health sciences university for the Church and its extensive network of health systems.

In addition to the sources of information identified in Fitch's applicable criteria specified below, this action was informed by information from Lumesis.

REFERENCES FOR SUBSTANTIALLY MATERIAL SOURCE CITED AS KEY DRIVER OF RATING

The principal sources of information used in the analysis are described in the Applicable Criteria.

ESG CONSIDERATIONS

Unless otherwise disclosed in this section, the highest level of ESG credit relevance is a score of '3'. This means ESG issues are credit-neutral or have only a minimal credit impact on the entity, either due to their nature or the way in which they are being managed by the entity. For more information on Fitch's ESG Relevance Scores, visit www.fitchratings.com/esg

FITCH RATINGS ANALYSTS

Mark Pascaris
Director
Primary Rating Analyst
Fitch Upgrades Loma Linda University Medical Center's (CA) IDR to 'BB+'; Outlook Stable

Michael Burger
Director
Secondary Rating Analyst
+1 415 796 9960
michael.burger@fitchratings.com

Kevin Holloran
Senior Director
Committee Chairperson
+1 512 813 5700
kevin.holloran@fitchratings.com

MEDIA CONTACTS

Sandro Scenga
New York
+1 212 908 0278
sandro.scenga@thefitchgroup.com

Additional information is available on www.fitchratings.com

PARTICIPATION STATUS

The rated entity (and/or its agents) or, in the case of structured finance, one or more of the transaction parties participated in the rating process except that the following issuer(s), if any, did not participate in the rating process, or provide additional information, beyond the issuer's available public disclosure.

APPLICABLE CRITERIA

U.S. Not-For-Profit Hospitals and Health Systems Rating Criteria (pub. 18 Nov 2020) (including rating assumption sensitivity)

Public Sector, Revenue-Supported Entities Rating Criteria – Effective from September 1, 2021 to April 27, 2023 (pub. 01 Sep 2021) (including rating assumption sensitivity)
APPLICABLE MODELS

Numbers in parentheses accompanying applicable model(s) contain hyperlinks to criteria providing description of model(s).

Portfolio Analysis Model (PAM), v2.0.0 (1)

ADDITIONAL DISCLOSURES

Dodd-Frank Rating Information Disclosure Form
Solicitation Status
Endorsement Policy

ENDORSEMENT STATUS

California Statewide Communities Development Authority EU Endorsed, UK Endorsed

DISCLAIMER & DISCLOSURES

All Fitch Ratings (Fitch) credit ratings are subject to certain limitations and disclaimers. Please read these limitations and disclaimers by following this link: https://www.fitchratings.com/understandingcreditratings. In addition, the following https://www.fitchratings.com/rating-definitions-document details Fitch's rating definitions for each rating scale and rating categories, including definitions relating to default. ESMA and the FCA are required to publish historical default rates in a central repository in accordance with Articles 11(2) of Regulation (EC) No 1060/2009 of the European Parliament and of the Council of 16 September 2009 and The Credit Rating Agencies (Amendment etc.) (EU Exit) Regulations 2019 respectively.

Published ratings, criteria, and methodologies are available from this site at all times. Fitch's code of conduct, confidentiality, conflicts of interest, affiliate firewall, compliance, and other relevant policies and procedures are also available from the Code of Conduct section of this site. Directors and shareholders' relevant interests are available at https://www.fitchratings.com/site/regulatory. Fitch may have provided another permissible or ancillary service to the rated entity or its related third parties. Details of permissible or ancillary service(s) for which the lead analyst is based in an ESMA- or FCA-registered Fitch Ratings company (or branch of such a company) can be found on the entity summary page for this issuer on the Fitch Ratings website.
In issuing and maintaining its ratings and in making other reports (including forecast information), Fitch relies on factual information it receives from issuers and underwriters and from other sources Fitch believes to be credible. Fitch conducts a reasonable investigation of the factual information relied upon by it in accordance with its ratings methodology, and obtains reasonable verification of that information from independent sources, to the extent such sources are available for a given security or in a given jurisdiction. The manner of Fitch's factual investigation and the scope of the third-party verification it obtains will vary depending on the nature of the rated security and its issuer, the requirements and practices in the jurisdiction in which the rated security is offered and sold and/or the issuer is located, the availability and nature of relevant public information, access to the management of the issuer and its advisers, the availability of pre-existing third-party verifications such as audit reports, agreed-upon procedures letters, appraisals, actuarial reports, engineering reports, legal opinions and other reports provided by third parties, the availability of independent and competent third-party verification sources with respect to the particular security or in the particular jurisdiction of the issuer, and a variety of other factors. Users of Fitch's ratings and reports should understand that neither an enhanced factual investigation nor any third-party verification can ensure that all of the information Fitch relies on in connection with a rating or a report will be accurate and complete. Ultimately, the issuer and its advisers are responsible for the accuracy of the information they provide to Fitch and to the market in offering documents and other reports. In issuing its ratings and its reports, Fitch must rely on the work of experts, including independent auditors with respect to financial statements and attorneys with respect to legal and tax matters. Further, ratings and forecasts of financial and other information are inherently forward-looking and embody assumptions and predictions about future events that by their nature cannot be verified as facts. As a result, despite any verification of current facts, ratings and forecasts can be affected by future events or conditions that were not anticipated at the time a rating or forecast was issued or affirmed.

The information in this report is provided “as is” without any representation or warranty of any kind, and Fitch does not represent or warrant that the report or any of its contents will meet any of the requirements of a recipient of the report. A Fitch rating is an opinion as to the creditworthiness of a security. This opinion and reports made by Fitch are based on established criteria and methodologies that Fitch is continuously evaluating and updating. Therefore, ratings and reports are the collective work product of Fitch and no individual, or group of individuals, is solely responsible for a rating or a report. The rating does not address the risk of loss due to risks other than credit risk, unless such risk is specifically mentioned. Fitch is not engaged in the offer or sale of any security. All Fitch reports have shared authorship. Individuals identified in a Fitch report were involved in, but are not
Fitch Upgrades Loma Linda University Medical Center’s (CA) IDR to 'BB+'; Outlook Stable

solely responsible for, the opinions stated therein. The individuals are named for contact purposes only. A report providing a Fitch rating is neither a prospectus nor a substitute for the information assembled, verified and presented to investors by the issuer and its agents in connection with the sale of the securities. Ratings may be changed or withdrawn at any time for any reason in the sole discretion of Fitch. Fitch does not provide investment advice of any sort. Ratings are not a recommendation to buy, sell, or hold any security. Ratings do not comment on the adequacy of market price, the suitability of any security for a particular investor, or the tax-exempt nature or taxability of payments made in respect to any security. Fitch receives fees from issuers, insurers, guarantors, other obligors, and underwriters for rating securities. Such fees generally vary from US$1,000 to US$750,000 (or the applicable currency equivalent) per issue. In certain cases, Fitch will rate all or a number of issues issued by a particular issuer, or insured or guaranteed by a particular insurer or guarantor, for a single annual fee. Such fees are expected to vary from US$10,000 to US$1,500,000 (or the applicable currency equivalent). The assignment, publication, or dissemination of a rating by Fitch shall not constitute a consent by Fitch to use its name as an expert in connection with any registration statement filed under the United States securities laws, the Financial Services and Markets Act of 2000 of the United Kingdom, or the securities laws of any particular jurisdiction. Due to the relative efficiency of electronic publishing and distribution, Fitch research may be available to electronic subscribers up to three days earlier than to print subscribers.

For Australia, New Zealand, Taiwan and South Korea only: Fitch Australia Pty Ltd holds an Australian financial services license (AFS license no. 337123) which authorizes it to provide credit ratings to wholesale clients only. Credit ratings information published by Fitch is not intended to be used by persons who are retail clients within the meaning of the Corporations Act 2001.

Fitch Ratings, Inc. is registered with the U.S. Securities and Exchange Commission as a Nationally Recognized Statistical Rating Organization (the “NRSRO”). While certain of the NRSRO’s credit rating subsidiaries are listed on Item 3 of Form NRSRO and as such are authorized to issue credit ratings on behalf of the NRSRO (see https://www.fitchratings.com/site/regulatory), other credit rating subsidiaries are not listed on Form NRSRO (the “non-NRSROs”) and therefore credit ratings issued by those subsidiaries are not issued on behalf of the NRSRO. However, non-NRSRO personnel may participate in determining credit ratings issued by or on behalf of the NRSRO.

Copyright © 2022 by Fitch Ratings, Inc., Fitch Ratings Ltd. and its subsidiaries. 33 Whitehall Street, NY, NY 10004. Telephone: 1-800-753-4824, (212) 908-0500. Fax: (212) 480-4435.

Fitch Upgrades Loma Linda University Medical Center's (CA) IDR to 'BB+'; Outlook Stable

The ratings above were solicited and assigned or maintained by Fitch at the request of the rated entity/issuer or a related third party. Any exceptions follow below.

ENDORSEMENT POLICY

Fitch’s international credit ratings produced outside the EU or the UK, as the case may be, are endorsed for use by regulated entities within the EU or the UK, respectively, for regulatory purposes, pursuant to the terms of the EU CRA Regulation or the UK Credit Rating Agencies (Amendment etc.) (EU Exit) Regulations 2019, as the case may be. Fitch’s approach to endorsement in the EU and the UK can be found on Fitch’s Regulatory Affairs page on Fitch’s website. The endorsement status of international credit ratings is provided within the entity summary page for each rated entity and in the transaction detail pages for structured finance transactions on the Fitch website. These disclosures are updated on a daily basis.

US Public Finance  Healthcare and Pharma  North America  United States